

Resource Summary Report

Generated by [dkNET](#) on Aug 15, 2026

Recombinant Anti-Firefly Luciferase antibody [EPR17790]

RRID:AB_2938620

Type: Antibody

Proper Citation

Abcam Cat# ab185924, RRID:AB_2938620

Antibody Information

URL: http://antibodyregistry.org/AB_2938620

Proper Citation: Abcam Cat# ab185924, RRID:AB_2938620

Target Antigen: Luciferase

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: Flow Cyt, ICC/IF, WB

Antibody Name: Recombinant Anti-Firefly Luciferase antibody [EPR17790]

Description: This recombinant monoclonal targets Luciferase

Target Organism: firefly

Clone ID: EPR17790

Antibody ID: AB_2938620

Vendor: Abcam

Catalog Number: ab185924

Record Creation Time: 20250820T001753+0000

Record Last Update: 20250820T075406+0000

Ratings and Alerts

- Used for immunohistochemistry by the Human Islet Research Network community. Contact(s): [Todd Evans](#), [David Ho](#), [Lorenz Studer](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for Recombinant Anti-Firefly Luciferase antibody [EPR17790].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wu CY, et al. (2025) Glucose restriction shapes pre-metastatic innate immune landscapes in the lung through exosomal TRAIL. *Cell*.

Hockings H, et al. (2025) Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control. *Cancer research*, 85(18), 3503.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Zhang Y, et al. (2024) Readthrough events in plants reveal plasticity of stop codons. *Cell reports*, 43(2), 113723.

Gan S, et al. (2024) Distinct tumor architectures and microenvironments for the initiation of breast cancer metastasis in the brain. *Cancer cell*, 42(10), 1693.

Shanley M, et al. (2024) Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. *Cancer cell*, 42(8), 1450.